Ziff Davis Invests $25M in Xyla to Integrate OpenEvidence into Everyday Health Group
August 2, 2023
Ziff Davis has made a $25 million minority equity investment in Xyla, Inc. and entered a long-term collaboration to integrate Xyla's OpenEvidence medical AI into Ziff Davis' Everyday Health Group. The strategic partnership is intended to accelerate AI-enabled products and drive enhanced, personalized engagement with healthcare professionals across Ziff Davis' healthcare properties.
- Buyers
- Ziff Davis, Inc.
- Targets
- Xyla, Inc. (OpenEvidence)
- Industry
- AI & Machine Learning
- Location
- Florida, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Ziff Davis Acquires Forensic and Compliance Systems, Email Industries and Well+Good
July 3, 2025
Media & Entertainment
Ziff Davis, Inc. completed three acquisitions in Q2 2025, acquiring Forensic and Compliance Systems, Email Industries, and Well+Good to expand its cybersecurity/martech capabilities and health & wellness media presence. The deals are expected to grow Ziff Davis' global customer base, provide access to new markets and broaden the company's product lineup; terms were not disclosed.
-
Zscaler Acquires SPLX to Expand AI Security Capabilities
November 3, 2025
Cybersecurity
Zscaler, Inc. has acquired AI security pioneer SPLX to extend the Zscaler Zero Trust Exchange with AI asset discovery, automated red teaming, runtime guardrails, and governance across the AI lifecycle. The deal integrates SPLX's technology for discovery, risk assessment and remediation into Zscaler's cloud security platform to help enterprises secure models, agent workflows, and RAG pipelines from development through deployment.
-
Zephyr AI Acquires Aster Insights
August 26, 2025
Biotechnology
Zephyr AI has acquired Aster Insights, a provider of scientific and clinical intelligence for oncology discovery, making Aster a wholly owned subsidiary to deepen Zephyr's real-world evidence and oncology data capabilities. Concurrently, Zephyr appointed Dr. Allen Chao, founder of Watson Pharmaceuticals, as CEO to lead the combined company's expansion of AI-driven precision medicine and clinical trial optimization.
-
ZS Acquires Trials.ai to Add AI-Driven Study Design
February 6, 2023
AI & Machine Learning
Global consulting and technology firm ZS has entered into a definitive agreement to acquire Trials.ai, an AI-powered clinical study design company. The acquisition will integrate Trials.ai's intelligent study-design capabilities into ZS's clinical development offerings to help sponsors identify risks, optimize participant experience and accelerate therapy development timelines.
-
Cohere Health Acquires ZignaAI
September 9, 2025
Healthcare Services
Cohere Health has acquired ZignaAI and launched a new Payment Integrity Suite centered on Cohere Validate, integrating pre-service authorization data with post-service claims and coding validation. The acquisition brings ZignaAI's AI-driven payment integrity and coding automation capabilities into Cohere's clinical intelligence platform to improve claims accuracy, reduce waste, and accelerate payment processes for health plans.
-
Audax Private Equity Makes Strategic Growth Investment in Integrate
December 20, 2021
Cloud & SaaS
Audax Private Equity completed a strategic growth investment in Integrate (Integrate.com, Inc.), a B2B demand marketing SaaS provider, in December 2021. The undisclosed investment will support Integrate's product development, customer growth, and geographic and vertical expansion for its Demand Acceleration Platform (DAP).
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.